Dear Sirs,

We report the rare case of a primary angiitis of the CNS (PACNS) with isolated spinal cord manifestation. This 44-year-old female presented diffuse dysesthesia with moderate progressive weakness of the lower limbs. There were no cerebral symptoms; cMRI was normal. The diagnosis of PACNS was made by a spinal cord biopsy demonstrating granulomatous vasculitis. The patient was successfully treated with steroids and methotrexate. During a 2 year follow-up our patient did not show any brain or other organ involvement.

The 44-year-old female presented with moderate progressive weakness of both legs and burning sensory symptoms of all limbs and the trunk. In addition to moderate paraparesis, the physical examination revealed a moderate pallhypesthesia of the legs with reduced vibratory sense and a diffuse hyp- and dysesthesia below the level of CD5. The family history was unremarkable for neurological diseases.

The MRI of the cervical spine showed a gadolinium-enhancing lesion in the posterior part of the myelon with intramedullary edema. This lesion extended from cervical vertebral bodies 2--7 (Fig. [1](#Fig1){ref-type="fig"}a).Fig. 1**a** MR study of the untreated patient. Sagittal FSE T1-weighted image shows a big, homogeneously enhancing lesion located in the cervical cord. **b** Follow-up MR study 24 months later. Sagittal FSE T1-weighted image shows no evidence of contrast enhancement of the cervical cord

The cerebral MRI and visual evoked potentials were entirely normal, the examination of the CSF revealed a slight pleocytosis (12 cells/mm^3^), cytological examination showed regular cells. Oligoclonal bands were absent which makes multiple sclerosis highly improbable.

Laboratory examinations did not reveal any evidence for either metabolic (vitamin-B12, folate), autoimmune or infectious disorder. We found no aquaporin-4-antibodies. With normal VEP, we had no evidence for neuromyelitis optica.

We started with intravenous high dose methylprednisolone therapy (1 g for 5 days), but symptoms relapsed after 3 months of disease freedom.

Before introduction of another immunosuppressive therapy, and to exclude a spinal lymphoma, a biopsy of the spinal lesion was taken. The neuropathological examination revealed a granulomatous vasculitis with transmural inflammation consisting of lymphocytes, epitheloid cells and giant cells (Fig. [2](#Fig2){ref-type="fig"}a--h). There was no evidence for systemic organ involvement assessed by thoracic and abdominal computer tomography.Fig. 2The histological features of primary spinal vasculitis. The neuropathological examination revealed vascular thrombosis (**a** 100× magnification, H&E staining) and vessel walls with transmural infiltration mainly consisting of several lymphocytes (**b** 200× magnification, H&E staining). In addition, there were epitheloid cells and giant cells (**c** 400× magnification, H&E staining) which are characteristic for a granulomatous vasculitis. There was no evidence for demyelination (**d** 200× magnification, LFB-PAS staining). Immunostainings indicated that the vessel walls were mainly infiltrated by CD3-positive T cells (**e** 200× magnification, immunohistochemistry for CD3) that were partly CD8-positive cytotoxic T cells (**f** 200× magnification, immunohistochemistry for CD8). Furthermore, several CD68-positive macrophages and activated microglial cells were detectable (**g** 200× magnification, immunohistochemistry for CD68). Within the CNS tissue, many reactive astrocytes could be observed (**h** 200× magnification, immunohistochemistry for glial fibrillic acidic protein)

Treatment was started with methotrexate (20 mg/week) combined with prednisolone (tapered from 80 to 10 mg/d within 6 weeks).

Neurological examination at 3 month intervals revealed normal findings except a slight dysesthesia in the legs.

A follow-up MRI after 24 months of treatment demonstrated an obvious regression of the signal intensities within the cervical cord (Fig. [1](#Fig1){ref-type="fig"}b), whereas the cMRI remained normal.

Spinal symptoms are a rare presentation of primary CNS vasculitis \[[@CR1]\]. The previously reported cases with spinal cord involvement also showed progressive paraparesis and dysesthesia as the most common clinical symptoms \[[@CR2]\]. However, usually these symptoms occur in the course of the disease and not at disease onset as in our case. A review of the literature showed only eight cases with initially pure spinal cord involvement \[[@CR3]\]; half of these cases developed brain lesions later on \[[@CR1], [@CR4]\].

The stereotactic biopsy remains the gold standard to assure the diagnosis of a CNS vasculitis \[[@CR5]\], but the diagnosis in daily clinical routine is often only based on clinical and imaging findings as well as the response to treatment. This might be a potential reason for overdiagnosing PACNS in clinical routine. As illustrated by our case, histological verification is crucial for the diagnosis.

The standard therapy for PACNS consists of corticosteroids (1 mg/kg prednisolone) and pulsed cyclophosphamide (0.5 mg/kg). The treatment with cyclophosphamide can have severe side effects \[[@CR6]\]. Monotherapy with steroids leads to higher recurrence rates \[[@CR7]\]. Since methotrexate has been successfully used in systemic vasculitis \[[@CR8]\], we started treatment with a combination of steroids and methotrexate. Our patient reached remission within 3 months and remains stable now more than 2 years later. In biopsy-proven PACNS of the spinal cord, methotrexate seems to be an effective and less toxic alternative to cyclophosphamide.
